The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise More: Lumanity and Parker Institute partner to support delivery of new immunotherapies Source: News
read moreAfter communicating with the FDA about font sizes for potential packaging on its investigational injection, Stealth Biotherapeutics’ CEO thought approval for the ultrarare genetic disease treatment was imminent. More: 'Hanging on by our fingernails': Stealth CEO questions efficiency behind FDA
read moreSanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. More: Sanofi spices up Type 1 diabetes awareness with sponsorship of new UK girl group Source: fierce
read moreSome two weeks after the public comment period closed for the Trump administration’s Section 232 investigation into the national security implications of pharmaceutical imports, a wide range of drugmakers, trade groups and foreign governments have largely aligned in opposition to
read moreCOVID-19 tweets from November 2020 have come back to haunt Pfizer once again. Fourteen months after an old tweet caused Pfizer new problems, pandemic-era social media posts linked to the drugmaker have again been found to have brought discredit to
read moreSix years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease treatment Tryptyr. More: Alcon gains first
read more© 1994 - 2026 B.M. Pharmaceuticals